Answers are grounded in this paper and cite their sources.
Cisplatin, but not its trans geometric isomer, is a potent anticancer drug whose biological activity is a consequence of the formation of covalent adducts between the platinum compound and certain bases in DNA. Two classes of proteins have recently been identified that bind preferentially to damaged sites: proteins that specifically recognize those sites as a first step in their repair, and those that bind to such sites by virtue of structural similarity between the modified DNA and their own natural binding sites. Both classes of proteins may be involved, perhaps in opposing ways, in the cytotoxic effect of the drug.
No takes yet. Share an insight, caveat, or question.
Zlatanova et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: